Grant · UKRI FLF
Elasmogen: Targeting the pathogenic Th17 cell axis in autoimmunity:developing a portfolio of novel.
Awarded a £1.58m Ukri Flf grant for "Targeting the pathogenic Th17 cell axis in autoimmunity:developing a portfolio of novel.".
- Company
- Elasmogen
- Funder
- UKRI FLF
- Amount
- £1.58m
- Programme
- Fellowship
- Role
- Lead organisation
- Dated
- 1 Dec 2021
- Record
- UKRI Gateway to Research
Elasmogen's other grants
Scottish tech in one email,
every Monday.
